New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
Glycosphingolipid lysosomal storage diseases are a small but challenging group of human disorders to treat. Although these appear to be monogenic disorders where the catalytic activity of enzymes in glycosphingolipid catabolism is impaired, the presentation and severity of disease is heterogeneous....
Main Authors: | Butters, T, Dwek, R, Platt, F |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2003
|
Registos relacionados
-
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Por: Jeyakumar, M, et al.
Publicado em: (2002) -
Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
Por: Butters, T, et al.
Publicado em: (2000) -
Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
Por: Platt, F, et al.
Publicado em: (2000) -
New developments in treating glycosphingolipid storage diseases.
Por: Platt, F, et al.
Publicado em: (2005) -
Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
Por: Priestman, D, et al.
Publicado em: (2008)